Clinical Trials

18 enrolled

Pancreatic Neoplasms

NCT06508463 2026-04-13

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

21 enrolled

Lymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT06696768 2026-04-13

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

24 enrolled

Colorectal Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

10 enrolled

Dermatologic

Skin Neoplasms

NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

800 enrolled

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

38 enrolled

Tumor-Agnostic

Neoplasms

NCT04837716 2026-02-19

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

12 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05391750 2026-02-17

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

7 enrolled

Plasma cell

Multiple Myeloma

NCT04848064 2026-02-10

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

DermatologicLymphoidOther hematologic neoplasm

12 enrolled

Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05443971 2026-02-06

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Phase 1 Terminated

4 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04081688 2026-02-05

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Phase 1 Terminated

16 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05154994 2026-01-27

RESOLVE

9 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

BreastGastrointestinalGynecologic

18 enrolled

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT02142803 2025-11-13

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

50 enrolled 16 charts

CNSGynecologic

Fallopian Tube Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT05943496 2025-11-06

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

LymphoidOther hematologic neoplasm

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06058663 2025-10-20

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

16 enrolled

Cholangiocarcinoma

NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

155 enrolled

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT03842228 2025-10-14

COD

39 enrolled 15 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT03801902 2025-09-23

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Phase 1 Completed

26 enrolled 17 charts

Lung Neoplasms

NCT04227028 2025-09-16

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

5 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04605731 2025-09-10

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

25 enrolled

Carcinoma, Hepatocellular

NCT04609592 2025-09-09

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

EndocrineGastrointestinalNET

10 enrolled

Gastro-enteropancreatic neuroendocrine tumor

NCT04007029 2025-09-05

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

24 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05136846 2025-06-04

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

28 enrolled